CD44 Participates in IP-10 Induction in Cells in Which Hepatitis C Virus RNA Is Replicating, through an Interaction with Toll-Like Receptor 2 and Hyaluronan

Journal of Virology

Volumn 86, Issue 11, 2012, Pages 6159-6170

  Abe, Takayuki ^a,e   Fukuhara, Takasuke ^a   Wen, Xiauyu ^a,f   Ninomiya, Akinori ^a   Moriishi, Kohji ^c   Maehara, Yoshihiko ^d   Takeuchi, Osamu ^b   Kawai, Taro ^b   Akira, Shizuo ^b   Matsuura, Yoshiharu ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HERMES ANTIGEN; HYALURONIC ACID; TOLL LIKE RECEPTOR 2; VIRUS RNA; CD44 PROTEIN, HUMAN; CXCL10 PROTEIN, HUMAN; TLR2 PROTEIN, HUMAN;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN EXPRESSION; PROTEIN INDUCTION; RECEPTOR BINDING; T LYMPHOCYTE ACTIVATION; VIRUS CELL INTERACTION; VIRUS REPLICATION; CELL LINE; DRUG POTENTIATION; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; PROTEIN BINDING; VIROLOGY;

HEPATITIS C VIRUS;

ANTIGENS, CD44; CELL LINE; CHEMOKINE CXCL10; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; HYALURONIC ACID; PROTEIN BINDING; RNA, VIRAL; TOLL-LIKE RECEPTOR 2; VIRUS REPLICATION;

EID: 84863596419     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06872-11     Document Type: Article

References (49)

1. Abe T, et al. 2007. Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J. Virol. 81:8953-8966.
2. Boisvert J, et al. 2003. Liver-infiltrating lymphocytes in end-stage hepatitis C virus: subsets, activation status, and chemokine receptor phenotypes. J. Hepatol. 38:67-75.
3. Butera D, et al. 2005. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 106:1175-1182.
4. Casrouge A, et al. 2011. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest. 121:308-317.
5. Diago M, et al. 2006. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 55:374-379.
6. Dolganiuc A, et al. 2003. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J. Immunol. 170:5615-5624.
7. Dolganiuc A, et al. 2004. Hepatitis C core and nonstructural 3 proteins trigger Toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 127:1513-1524.
8. Ebihara T, Shingai M, Matsumoto M, Wakita T, Seya T. 2008. Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. Hepatology 48:48-58.
9. Guechot J, et al. 2000. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J. Hepatol. 32:447-452.
10. Günthert U, et al. 1998. Functional involvement of CD44, a family of cell adhesion molecules, in immune responses, tumour progression and haematopoiesis. Adv. Exp. Med. Biol. 451:43-49.
11. Günthert U, et al. 1995. Are CD44 variant isoforms involved in human tumour progression? Cancer Surv. 24:19-42.
12. Harvey CE, et al. 2003. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J. Leukoc. Biol. 74:360-369.
13. Helbig KJ, et al. 2009. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J. Virol. 83:836-846.
14. Helbig KJ, et al. 2004. Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation. Hepatology 39:1220-1229.
15. Herrlich P, et al. 1998. How tumor cells make use of CD44. Cell. Adhes. Commun. 6:141-147.
16. Heydtmann M, Adams DH. 2009. Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology 49:676-688.
17. Itoh Y, et al. 2001. Clinical significance of elevated serum interferoninducible protein-10 levels in hepatitis C virus carriers with persistently normal serum transaminase levels. J. Viral. Hepat. 8:341-348.
18. Jiang D, et al. 2005. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 11:1173-1179.
19. Jiang D, Liang J, Noble PW. 2007. Hyaluronan in tissue injury and repair. Annu. Rev. Cell Dev. Biol. 23:435-461.
20. Kaimori A, et al. 2004. Pseudotype hepatitis C virus enters immature myeloid dendritic cells through the interaction with lectin. Virology 324: 74-83.
21. Kawana H, et al. 2008. CD44 suppresses TLR-mediated inflammation. J. Immunol. 180:4235-4245.
22. Lagging M, et al. 2006. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 44:1617-1625.
23. Larrubia JR, Benito-Martinez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. 2008. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J. Gastroenterol. 14:7149-7159.
24. Larrubia JR, et al. 2007. The role of CCR5/CXCR3 expressing CD8 cells in liver damage and viral control during persistent hepatitis C virus infection. J. Hepatol. 47:632-641.
25. Lemon SM. 2010. Induction and evasion of innate antiviral responses by hepatitis C virus. J. Biol. Chem. 285:22741-22747.
26. Leroy V, et al. 2003. Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. Hepatology 38:829-841.
27. Liang J, et al. 2007. CD44 is a negative regulator of acute pulmonary inflammation and lipopolysaccharide-TLR signaling in mouse macrophages. J. Immunol. 178:2469-2475.
28. Lohmann V, et al. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
29. Marukian S, et al. 2008. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48:1843-1850.
30. McHutchison JG, et al. 2000. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J. Gastroenterol. Hepatol. 15:945-951.
31. Mielgo A, van Driel M, Bloem A, Landmann L, Günthert U. 2006. A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ. 13:465-477.
32. Moriishi K, Matsuura Y. 2003. Mechanisms of hepatitis C virus infection. Antivir. Chem. Chemother. 14:285-297.
33. Narumi S, et al. 1997. Expression of IFN-inducible protein-10 in chronic hepatitis. J. Immunol. 158:5536-5544.
34. Okamoto T, et al. 2008. A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication. J. Virol. 82:3480-3489.
35. Patel K, et al. 2003. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J. Gastroenterol. Hepatol. 18:253-257.
36. Patzwahl R, Meier V, Ramadori G, Mihm S. 2001. Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization. J. Virol. 75:1332-1338.
37. Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. 2001. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 75:6209-6211.
38. Ponta H, Sherman L, Herrlich PA. 2003. CD44: from adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 4:33-45.
39. Radkowski M, et al. 2004. Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor-alpha and interleukin 8. J. Gen. Virol. 85:47-59.
40. Romero AI, et al. 2006. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J. Infect. Dis. 194:895-903.
41. Scheibner KA, et al. 2006. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J. Immunol. 177:1272-1281.
42. Shields PL, et al. 1999. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J. Immunol. 163:6236-6243.
43. Shiina M, Rehermann B. 2008. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 47:385-395.
44. Takeuchi O, Akira S. 2010. Pattern recognition receptors and inflammation. Cell 140:805-820.
45. Ueno T, et al. 1995. Serum hyaluronate predicts response to interferonalpha therapy in patients with chronic hepatitis C. Hepatogastroenterology 42:522-527.
46. Wakita T, et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
47. Wang J, Holmes TH, Cheung R, Greenberg HB, He XS. 2004. Expression of chemokine receptors on intrahepatic and peripheral lymphocytes in chronic hepatitis C infection: its relationship to liver inflammation. J. Infect. Dis. 190:989-997.
48. Wong VS, et al. 1998. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J. Viral Hepat. 5:187-192.
49. Zeremski M, et al. 2008. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 48:1440-1450.